Home Casteddu.com	FAQ My Amedeo About	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Breast Cancer

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 33 articles: HTML format

Single Articles

August 2009
1. SIMS JT , Plattner R
   MTT assays cannot be utilized to study the effects of STI571/Gleevec on the viability of solid tumor cell lines.
   Cancer Chemother Pharmacol. 2009;64:629-33.
   PubMed     Related articles    Abstract available
   
   
   
2. FURUYA Y , Yanagie H, Wakahara T, Mishina Y, et al
   Improved survival in patients with breast rhabdoid tumors with multi-agent adjuvant chemotherapy combined with irradiation.
   Cancer Chemother Pharmacol. 2009;64:623-7.
   PubMed     Related articles    Abstract available
   
   
   July 2009
3. ABU AJAJ K , Graeser R, Fichtner I, Kratz F, et al
   In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B.
   Cancer Chemother Pharmacol. 2009;64:413-8.
   PubMed     Related articles    Abstract available
   
   
   
4. ISHIDA T , Kiba T, Takeda M, Matsuyama K, et al
   Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.
   Cancer Chemother Pharmacol. 2009;64:361-9.
   PubMed     Related articles    Abstract available
   
   
   June 2009
5. NIETO Y , Aramendia JM, Espinos J, De la Cruz S, et al
   Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
   Cancer Chemother Pharmacol. 2009.
   PubMed     Related articles    Abstract available
   
   
   
6. ENDO M , Miwa M, Ura M, Tanimura H, et al
   A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts.
   Cancer Chemother Pharmacol. 2009.
   PubMed     Related articles    Abstract available
   
   
   May 2009
7. DU G , Lin H, Wang M, Zhang S, et al
   Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1alpha in tumor and normal cells.
   Cancer Chemother Pharmacol. 2009.
   PubMed     Related articles    Abstract available
   
   
   
8. WATERS SH , Gillibrand A, Berry H, Kumar S, et al
   Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
   Cancer Chemother Pharmacol. 2009.
   PubMed     Related articles    Abstract available
   
   
   
9. KUREBAYASHI J , Nukatsuka M, Sonoo H, Uchida J, et al
   Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
   Cancer Chemother Pharmacol. 2009.
   PubMed     Related articles    Abstract available
   
   
   
10. AKIYOSHI T , Matzno S, Sakai M, Okamura N, et al
    The potential of vitamin K(3) as an anticancer agent against breast cancer that acts via the mitochondria-related apoptotic pathway.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Related articles    Abstract available
    
    
    April 2009
11. JOBSON AG , Willmore E, Tilby MJ, Mistry P, et al
    Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases.
    Cancer Chemother Pharmacol. 2009;63:889-901.
    PubMed     Related articles    Abstract available
    
    
    
12. STOEGER SM , Cowan KH
    Characterization of kinase suppressor of Ras-1 expression and anticancer drug sensitivity in human cancer cell lines.
    Cancer Chemother Pharmacol. 2009;63:807-18.
    PubMed     Related articles    Abstract available
    
    
    
13. BAR-SELA G , Haim N
    Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature.
    Cancer Chemother Pharmacol. 2009;63:779-82.
    PubMed     Related articles    Abstract available
    
    
    March 2009
14. RIXE O , Franco SX, Yardley DA, Johnston SR, et al
    A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Related articles    Abstract available
    
    
    February 2009
15. RUFF P , Vorobiof DA, Jordaan JP, Demetriou GS, et al
    A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Related articles    Abstract available
    
    
    January 2009
16. NOLE F , Crivellari D, Mattioli R, Pinotti G, et al
    Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Related articles    Abstract available
    
    
    
17. BOZIONELOU V , Kalbakis K, Vamvakas L, Agelaki S, et al
    A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer.
    Cancer Chemother Pharmacol. 2009.
    PubMed     Related articles    Abstract available
    
    
    
18. HARDEE ME , Eapen RJ, Rabbani ZN, Dreher MR, et al
    Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors.
    Cancer Chemother Pharmacol. 2009;63:219-28.
    PubMed     Related articles    Abstract available
    
    
    December 2008
19. SCHMID P , Krocker J, Kreienberg R, Klare P, et al
    Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial.
    Cancer Chemother Pharmacol. 2008.
    PubMed     Related articles    Abstract available
    
    
    
20. MA Z , Molavi O, Haddadi A, Lai R, et al
    Resveratrol analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol.
    Cancer Chemother Pharmacol. 2008;63:27-35.
    PubMed     Related articles    Abstract available
    
    
    November 2008
21. TANAKA S , Nohara T, Iwamoto M, Sumiyoshi K, et al
    Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer.
    Cancer Chemother Pharmacol. 2008.
    PubMed     Related articles    Abstract available
    
    
    
22. COLOZZA M , Minenza E, Gori S, Fenocchio D, et al
    Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab.
    Cancer Chemother Pharmacol. 2008.
    PubMed     Related articles   
    
    
    
23. O'REILLY T , Wartmann M, Brueggen J, Allegrini PR, et al
    Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    Cancer Chemother Pharmacol. 2008;62:1045-54.
    PubMed     Related articles    Abstract available
    
    
    October 2008
24. AZAB SS , Salama SA, Hassan MH, Khalifa AE, et al
    2-Methoxyestradiol reverses doxorubicin resistance in human breast tumor xenograft.
    Cancer Chemother Pharmacol. 2008;62:893-902.
    PubMed     Related articles    Abstract available
    
    
    September 2008
25. YUAN J , Lv H, Peng B, Wang C, et al
    Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer.
    Cancer Chemother Pharmacol. 2008.
    PubMed     Related articles    Abstract available
    
    
    
26. KANG HJ , Kim HJ, Kwon SH, Kang BD, et al
    BRCA1 modulates sensitivity to 5F-203 by regulating xenobiotic stress-inducible protein levels and EROD activity.
    Cancer Chemother Pharmacol. 2008;62:689-97.
    PubMed     Related articles    Abstract available
    
    
    August 2008
27. CAMPONE M , Blasinska-Morawiec M, Tekiela A, Koralewski P, et al
    Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer.
    Cancer Chemother Pharmacol. 2008.
    PubMed     Related articles    Abstract available
    
    
    
28. LOIBL S , Murmann C, Schwedler K, Warm M, et al
    Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
    Cancer Chemother Pharmacol. 2008.
    PubMed     Related articles    Abstract available
    
    
    
29. OSAKO T , Ito Y, Ushijima M, Takahashi S, et al
    Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
    Cancer Chemother Pharmacol. 2008.
    PubMed     Related articles    Abstract available
    
    
    July 2008
30. MA G , Tabanca N, Husnu Can Baser K, Kirimer N, et al
    Inhibition of NF-kappaB-mediated transcription and induction of apoptosis in human breast cancer cells by epoxypseudoisoeugenol-2-methyl butyrate.
    Cancer Chemother Pharmacol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    June 2008
31. PARK BB , Uhm JE, Cho EY, Choi YL, et al
    Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes?
    Cancer Chemother Pharmacol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
32. GUO F , Letrent SP, Munster PN, Britten CD, et al
    Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Cancer Chemother Pharmacol. 2008;62:97-109.
    PubMed     Related articles    Abstract available
    
    
    May 2008
33. LACROIX M
    MDA-MB-435 cells are from melanoma, not from breast cancer.
    Cancer Chemother Pharmacol. 2008;.
    PubMed     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: